semaglutide for ra Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy The Multidisciplinary Approach to GLP-1

The World Health Organization's December 2025 guidelines emphasized the importance of resistance training to protect muscle mass during GLP-1 therapy, acknowledging this as a limitation of current treatment approaches [49]

Helps Reduce Inflammation Due to Its Tannin and Saponin Content

Variations in the GLP1R gene (rs6923761) and the FTO gene (rs9939609)a major regulator of appetite and energy expenditureaffect how strongly you respond to GLP-1 therapy

In 52 global controlled and uncontrolled clinical trials of HUMIRA in adult subjects with RA, PsA, AS, CD, UC, Ps, HS and UV with a median duration of approximately 0.7 years, including 24,605 subjects and over 40,215 patient-years of HUMIRA, the observed rate of lymphomas was approximately 0.11 per 100 patient-years

Current evidence suggests there may be a link between GLP-1 medications and hair loss, particularly with semaglutide (Wegovy) and tirzepatide (Mounjaro), but researchers have not proven that the medication itself directly causes hair loss